Geodon: Effective Atypical Antipsychotic for Symptom Control
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.32 | $46.44 (0%) | 🛒 Add to cart |
| 30 | $1.63 | $69.66 $49.02 (30%) | 🛒 Add to cart |
| 60 | $1.22 | $139.32 $73.10 (48%) | 🛒 Add to cart |
| 90 | $1.02 | $208.98 $92.02 (56%) | 🛒 Add to cart |
| 120 | $0.82 | $278.64 $98.04 (65%) | 🛒 Add to cart |
| 180 | $0.74 | $417.96 $132.44 (68%) | 🛒 Add to cart |
| 270 | $0.69 | $626.94 $185.76 (70%) | 🛒 Add to cart |
| 360 | $0.65
Best per pill | $835.92 $235.64 (72%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.96 | $39.56 (0%) | 🛒 Add to cart |
| 20 | $2.71 | $79.12 $54.18 (32%) | 🛒 Add to cart |
| 30 | $1.89 | $118.68 $56.76 (52%) | 🛒 Add to cart |
| 60 | $1.36 | $237.36 $81.70 (66%) | 🛒 Add to cart |
| 90 | $1.18 | $356.04 $105.78 (70%) | 🛒 Add to cart |
| 120 | $1.09 | $474.72 $130.72 (72%) | 🛒 Add to cart |
| 180 | $1.04 | $712.08 $187.48 (74%) | 🛒 Add to cart |
| 270 | $1.02 | $1068.12 $274.34 (74%) | 🛒 Add to cart |
| 360 | $1.00
Best per pill | $1424.16 $359.48 (75%) | 🛒 Add to cart |
Geodon (ziprasidone) is an atypical antipsychotic medication indicated for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder. It functions by modulating dopamine and serotonin activity in the brain, helping to restore neurotransmitter balance. Clinically proven to reduce positive and negative symptoms, it offers a favorable metabolic profile with lower weight gain potential compared to some alternatives. Available in oral capsules and intramuscular injection formulations, it provides flexible administration options for both acute and maintenance therapy.
Features
- Active ingredient: ziprasidone hydrochloride
- Available in 20 mg, 40 mg, 60 mg, and 80 mg oral capsules
- Intramuscular injection formulation for acute agitation (10 mg/mL after reconstitution)
- Serotonin 5-HT2A and dopamine D2 receptor antagonist
- FDA-approved for schizophrenia and bipolar disorder
- Requires administration with food for optimal absorption
Benefits
- Reduces hallucinations, delusions, and disorganized thinking in schizophrenia
- Stabilizes mood swings and manic symptoms in bipolar disorder
- Lower risk of significant weight gain compared to other atypical antipsychotics
- Minimal effect on glucose metabolism and lipid profiles
- Rapid-acting intramuscular formulation for acute agitation management
- Once-daily dosing possible for maintenance therapy after initial titration
Common use
Geodon is primarily prescribed for the management of schizophrenia in adults, helping control both positive symptoms (such as hallucinations and delusions) and negative symptoms (including social withdrawal and apathy). It is also approved for the treatment of acute manic or mixed episodes in bipolar I disorder, either as monotherapy or as an adjunct to lithium or valproate. Some off-label uses include maintenance treatment in bipolar disorder and adjunctive therapy in treatment-resistant depression, though these applications require careful clinical consideration.
Dosage and direction
Schizophrenia: Initial dose is 20 mg twice daily with food. May increase to 60 mg or 80 mg twice daily based on clinical response and tolerance. Maximum recommended dose is 160 mg daily.
Bipolar mania: Initial dose is 40 mg twice daily with food. May increase to 60 mg or 80 mg twice daily. Dose adjustments should occur at intervals of no less than 2 days.
IM injection: 10-20 mg every 2 hours up to maximum 40 mg daily for acute agitation. Oral therapy should follow as soon as clinically appropriate.
All doses must be taken with at least 500 calories of food to ensure adequate absorption. Regular monitoring of ECG parameters is recommended, particularly during dose titration.
Precautions
- Requires baseline and periodic ECG monitoring due to potential QTc prolongation
- Use with caution in patients with cardiovascular disease or history of arrhythmias
- May cause orthostatic hypotension, especially during initial dose titration
- Monitor for signs of neuroleptic malignant syndrome (NMS)
- Observe for tardive dyskinesia, particularly in long-term use
- Caution advised in patients with seizure disorders or conditions that lower seizure threshold
- Use carefully in elderly patients with dementia-related psychosis due to increased mortality risk
- Regular monitoring of electrolytes recommended in patients at risk for hypokalemia or hypomagnesemia
Contraindications
- History of known hypersensitivity to ziprasidone or any component of the formulation
- Patients with known prolonged QTc interval (≥500 msec)
- Concurrent use with other drugs known to prolong QTc interval
- Recent acute myocardial infarction
- Uncompensated heart failure
- History of congenital long QT syndrome
- Severe hepatic impairment
Possible side effect
Common (≥5%):
- Somnolence (14%)
- Extrapyramidal symptoms (8%)
- Dizziness (8%)
- Nausea (8%)
- Constipation (8%)
- Akathisia (8%)
- Respiratory tract infection (8%)
Less common (1-5%):
- Orthostatic hypotension
- Rash
- Weight gain
- Increased cough
- Diarrhea
- Blurred vision
Rare (<1%):
- QTc prolongation
- Tardive dyskinesia
- Neuroleptic malignant syndrome
- Seizures
- Priapism
- Hyperglycemia
Drug interaction
- Contraindicated: Other QTc-prolonging agents (quinolones, class IA/III antiarrhythmics, methadone)
- Significant: Ketoconazole and other potent CYP3A4 inhibitors may increase ziprasidone levels
- Moderate: Carbamazepine and other CYP3A4 inducers may decrease ziprasidone levels
- Caution advised: Antihypertensive agents (additive hypotension)
- Monitor: Levodopa and dopamine agonists (antagonistic effects)
- Potential interaction: Centrally-acting drugs and alcohol (additive sedation)
Missed dose
If a dose is missed, take it as soon as remembered unless it is close to the time for the next scheduled dose. Do not double the dose to make up for a missed one. Resume regular dosing schedule with the next dose. If multiple doses are missed, contact healthcare provider for guidance on resumption of therapy, as retitration may be necessary.
Overdose
Symptoms may include sedation, hypotension, and QTc prolongation. Cases of torsades de pointes have been reported in the setting of overdose. Management involves immediate medical attention, cardiac monitoring, and supportive care. There is no specific antidote. Gastric lavage may be considered if presentation is early. Activated charcoal may be administered. Maintain airway and provide symptomatic treatment for hypotension and CNS depression. Continuous ECG monitoring is essential for at least 24 hours.
Storage
Store at room temperature (15-30°C or 59-86°F). Keep in original container, tightly closed. Protect from light and moisture. Do not freeze. Keep out of reach of children and pets. Do not use if capsules appear damaged or discolored. For IM formulation, use immediately after reconstitution and discard any unused portion.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Geodon is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to medication may vary. Always follow your healthcare provider’s instructions regarding dosage, administration, and monitoring. Report any side effects or concerns to your healthcare provider promptly. Do not discontinue medication without medical supervision.
Reviews
“Geodon has been effective in managing my patient’s positive symptoms with minimal metabolic impact. The twice-daily dosing with food requires patient education but generally good adherence.” - Psychiatrist, 15 years experience
“Notable improvement in manic symptoms within the first week of treatment. Weight-neutral profile makes it preferable for patients concerned about metabolic side effects.” - Bipolar specialist
“Some patients experience akathisia initially, but this often resolves with dose adjustment or adjunctive therapy. ECG monitoring is essential but manageable in clinical practice.” - Clinical pharmacist
“Effective for acute agitation with IM formulation. Transition to oral therapy generally smooth. Food requirement for absorption is the main compliance challenge noted.” - Emergency psychiatry team